PriceTargets.com logo

NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 1,988.55 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.24 As of 08/8/2022 01:00 AM ET
▲ +0.01 (4.36%)

This chart shows the closing price for ACRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AcelRx Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACRX

Analyst Price Target is $5.00
▲ +1,988.55% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for AcelRx Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 1,988.55% upside from the last price of $0.24.

This chart shows the closing price for ACRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in AcelRx Pharmaceuticals. This rating has held steady since February 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
8/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/11/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/8/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2022HC WainwrightDowngradeBuy ➝ NeutralHigh
3/11/2022Cantor FitzgeraldReiterated RatingOverweightHigh
8/17/2021HC WainwrightLower Price TargetBuy$7.00 ➝ $5.00High
8/13/2020Credit Suisse GroupBoost Price TargetUnderperform$0.69 ➝ $0.84Low
7/20/2020Credit Suisse GroupDowngradeNeutral ➝ Underperform$1.00 ➝ $0.69High
5/12/2020LADENBURG THALM/SH SHReiterated RatingBuy$8.00Low
3/17/2020HC WainwrightLower Price TargetBuy$9.00 ➝ $7.00High
11/11/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$7.00 ➝ $2.00High
11/8/2019HC WainwrightReiterated RatingBuy$9.00Medium
8/5/2019Credit Suisse GroupInitiated CoverageOutperform ➝ Outperform$7.00Medium
7/10/2019Credit Suisse GroupReiterated RatingOutperformMedium
5/9/2019LADENBURG THALM/SH SHReiterated RatingBuy$10.00High
4/24/2019B. RileyInitiated CoverageBuy ➝ Buy$6.50High
3/8/2019LADENBURG THALM/SH SHSet Price TargetBuy$10.00High
2/15/2019Credit Suisse GroupInitiated CoverageOutperform$7.00High
1/29/2019Cantor FitzgeraldSet Price TargetBuy$9.00Low
12/12/2018HC WainwrightReiterated RatingBuy$9.00High
12/11/2018OppenheimerReiterated RatingHoldHigh
12/11/2018Cantor FitzgeraldReiterated RatingBuy$9.00High
11/6/2018HC WainwrightReiterated RatingBuy$9.00High
11/5/2018Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $9.00Low
11/2/2018LADENBURG THALM/SH SHSet Price TargetBuy$10.00High
11/2/2018Cantor FitzgeraldSet Price TargetBuy$8.00High
10/25/2018Cantor FitzgeraldSet Price TargetBuy$8.00High
10/23/2018B. RileyInitiated CoverageBuy ➝ Buy$9.00High
10/22/2018Royal Bank of CanadaSet Price TargetBuy$7.00Medium
10/15/2018HC WainwrightBoost Price TargetPositive ➝ Buy$7.00 ➝ $8.00High
10/15/2018OppenheimerReiterated RatingHoldHigh
10/15/2018Cantor FitzgeraldSet Price TargetBuy$8.00High
10/15/2018Jefferies Financial GroupUpgradeHold ➝ Buy$8.00High
10/10/2018LADENBURG THALM/SH SHReiterated RatingBuy ➝ Buy$7.00 ➝ $10.00High
10/9/2018OppenheimerReiterated RatingHoldHigh
10/8/2018Cantor FitzgeraldSet Price TargetBuy$6.00Medium
10/1/2018Cantor FitzgeraldSet Price TargetBuy$6.00Medium
9/20/2018Cantor FitzgeraldReiterated RatingBuy$6.00Low
8/16/2018LADENBURG THALM/SH SHInitiated CoverageBuy$7.00High
8/7/2018HC WainwrightReiterated RatingBuyLow
8/3/2018OppenheimerReiterated RatingHoldHigh
8/2/2018Cantor FitzgeraldReiterated RatingBuy$6.00High
7/12/2018OppenheimerInitiated CoverageHoldHigh
6/14/2018Cantor FitzgeraldReiterated RatingOverweightMedium
6/11/2018Cantor FitzgeraldInitiated CoverageBuy$6.00Low
10/27/2017HC WainwrightReiterated RatingBuy$5.00N/A
10/13/2017Piper Jaffray CompaniesReiterated RatingHold$2.00N/A
10/13/2017Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$6.00 ➝ $5.00N/A
10/13/2017Jefferies Financial GroupDowngradeBuy ➝ HoldN/A
10/12/2017Roth CapitalSet Price TargetBuy$8.00N/A
10/3/2017HC WainwrightReiterated RatingBuy$10.00High
8/25/2017Royal Bank of CanadaSet Price TargetBuy$6.00Low
8/10/2017Roth CapitalReiterated RatingBuy$12.50High
8/9/2017Stifel NicolausUpgradeHold ➝ BuyHigh
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/11/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
2/10/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/12/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/11/2022
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/11/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
6/10/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/10/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/9/2022

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
AcelRx Pharmaceuticals logo
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Read More

Today's Range

Now: $0.24
Low: $0.22
High: $0.24

50 Day Range

MA: $0.23
Low: $0.18
High: $0.35

52 Week Range

Now: $0.24
Low: $0.16
High: $1.25

Volume

1,002,843 shs

Average Volume

1,437,678 shs

Market Capitalization

$35.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of AcelRx Pharmaceuticals?

The following equities research analysts have issued research reports on AcelRx Pharmaceuticals in the last twelve months: Cantor Fitzgerald, HC Wainwright, and StockNews.com.
View the latest analyst ratings for ACRX.

What is the current price target for AcelRx Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for AcelRx Pharmaceuticals in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 1,988.6%. HC Wainwright has the highest price target set, predicting ACRX will reach $5.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $5.00 for AcelRx Pharmaceuticals in the next year.
View the latest price targets for ACRX.

What is the current consensus analyst rating for AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACRX will outperform the market and that investors should add to their positions of AcelRx Pharmaceuticals.
View the latest ratings for ACRX.

What other companies compete with AcelRx Pharmaceuticals?

Other companies that are similar to AcelRx Pharmaceuticals include Aptinyx, eFFECTOR Therapeutics, IMARA, Angion Biomedica and Cumberland Pharmaceuticals. Learn More about companies similar to AcelRx Pharmaceuticals.

How do I contact AcelRx Pharmaceuticals' investor relations team?

AcelRx Pharmaceuticals' physical mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company's listed phone number is (650) 216-3500 and its investor relations email address is [email protected] The official website for AcelRx Pharmaceuticals is www.acelrx.com. Learn More about contacing AcelRx Pharmaceuticals investor relations.